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Letters to the EditorDo EASL and mRECIST responses have independent effects
on survival in hepatocellular carcinoma patients treated
with transarterial embolization?To the Editor:
We read with interest the paper by Gillmore et al. [1] regarding
the impact of the European Association for the Study of the Liver
(EASL) and modiﬁed Response Evaluation Criteria In Solid Tumors
(mRECIST) on survival in hepatocellular carcinoma (HCC) patients
treated with transarterial embolization. The authors compared
RECIST1.1, EASL and mRECIST criteria and found that overall
responses to EASL and mRECIST at 2–3 months after therapy
were associated with survival.
We consider this conclusion to be very important in clinical
practice. Riaz et al. [2] evaluated the response in the primary
index lesion after loco-regional therapy in HCC patients and
found that the median time to the RECIST response was
7.7 months; this value was only 1.6 months when EASL criteria
were used. We can attribute this result to the fact that, in contrast
to the EASL criteria, the RECIST criteria do not address measures
of antitumor activity other than tumor shrinkage, whereas loco-
regional treatments such as transarterial chemoembolization
(TACE) often cause acute tumor necrosis, which may not always
be accompanied by a change in tumor size [3]. Based on the
above considerations, RECIST is not applicable during the early
postoperative period.
Nevertheless, as it was a retrospective non-controlled study,
some aspects of the investigation may preclude the possibility
of drawing deﬁnitive conclusions. According to this study,
patients deﬁned as responders obtained a longer overall survival
compared to non-responders, then, we wonder whether the liver
function between the two groups was comparable. As is well
known, the determination of a prognosis is much more complex
in HCC patients than in patients with other solid neoplasms
because of the degree of liver dysfunction, which is related to
the underlying chronic liver disease as well as the related treat-
ment. For this reason, liver function should be assessed for the
reliable establishment of prognosis [4]. In the current study, 13
patients classiﬁed as Child-Pugh class B were included; we sus-
pect that the different survival between responders and non-
responders may not only represent different response, but also
be affected by different liver functions.A B
Fig. 1. Complete response according to mRECIST and EASL in a hepatocellular carci
CT image obtained at baseline demonstrates elliptical enhancement (arrow). At that t
image obtained 7 weeks after transarterial chemoembolization reveals full uptake of lipi
to EASL and mRECIST. The liver function was reclassiﬁed as Child-Pugh B9. (C) Six mo
retention (arrow). Therefore, the tumor response should still be categorized as CR. Liv
4 months later.
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initial response to percutaneous ablation were independent pre-
dictors of survival for HCC patients. Child-Pugh class A patients
who displayed an initial complete response could even achieve
42% survival at 5 years. Riaz et al. [2] and Memon et al. [6] also
demonstrated that, except for tumor response, liver function is
another important factor signiﬁcantly related to outcome by sta-
tistical analysis.
We hold the opinion that, on the one hand, to assess the asso-
ciation between response and survival, it is imperative to elimi-
nate the inﬂuence of confounding factors such as liver function.
Therefore, the differences in outcomes represent differences in
the tumor response. While on the other hand, to predict survival,
we should take into account liver function even if it is not signif-
icantly related to survival by statistical analysis, since it is neces-
sary but not sufﬁcient to make a good prognostic variable only to
analyse an association between variables and survival
statistically by ‘information criterion’ or ‘measure of gradient’
[7]. Particularly, liver function at the time of the evaluation
should be attached importance to. As for some of our cases,
patients with well-preserved liver function at baseline under-
went successful transarterial therapy and obtained tumor
responses but died of liver failure after a short while (Fig. 1A–
C). It is therefore not possible to rule out changes in liver function
after treatment.
Another question relates to whether a single assessment
was sufﬁcient to estimate the patient responses. Response is
a time-dependent variable, which is determined by two obser-
vations performed not less than 4 weeks apart [8]. The dura-
tion of the response is a critical issue. A total reduction in
tumor bulk is meaningless if the duration is short-lived
because of tumor recurrence or the appearance of new lesions
as well as extrahepatic metastasis or vascular invasion [9]. For
a response to be conﬁrmed, it should be demonstrated on a
second examination at a certain time after its initial evaluation.
It may therefore be inappropriate to assess the response only
once.C
noma patient after transarterial chemoembolization. (A) The contrast-enhanced
ime, liver function was classiﬁed as Child-Pugh A6. (B) The contrast-enhanced CT
odol in the tumor (arrow), which demonstrates a CR (complete response) according
nths after treatment, the contrast-enhanced CT image shows no change in lipiodol
er function deteriorated to Child-Pugh C >10, and the patient died of liver failure
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Although they are convenient and practical in assessing tumor
response and predicting survival, the EASL and mRECIST criteria
using computed tomography (CT) may overestimate the extent
of necrosis owing to the use of lipiodol uptake and retention as
surrogates for necrosis [10]. Patients classiﬁed as CR may have
residual disease at the time of the explant. It has been veriﬁed
that the presence of extensive necrosis induced by chemoembo-
lization correlates with outcome [10]. Then better imaging
modality should be explored to make radiologic necrosis more
precisely represent pathologic necrosis so as to provide a valida-
tion for the accurate use of mRECIST and EASL. In conclusion, fur-
ther study is needed for more reasonable and comprehensive
predictions of outcome.
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To the Editor:
We thank Wang and colleagues for their critical appraisal of our
paper which explores the prognostic importance of early
response assessment in patients with hepatocellular cancer
(HCC) undergoing transarterial embolisation [1]. Wang et al.
correctly point out that the prognosis for HCC patients is
determined by many factors, including liver function, and are
concerned that Child–Pugh score may have been a confounding
factor in our analysis. Of the 83 patients included in the study,
69 had Child–Pugh A liver scores and only 13 had Child–Pugh B.
As shown in Table 1, the distribution of Child–Pugh A and B was
almost identical in the responding and non-responding group
regardless of the response criteria used. This is expected since
response alone should not be inﬂuenced by Child–Pugh score.
With regards to survival, we analysed 10 prognostic factors
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including Child–Pugh score. Of these 10, only ﬁve had a signif-
icant association with survival (performance status, number of
lesions (unifocal or multifocal), hepatitis B and C aetiologies
and baseline pre-treatment AFP all p <0.05). Child–Pugh score
did not (p = 0.91), possibly due to the small number of
Child–Pugh B patients. All 10 factors were used to build the
multivariate model. Backwards selection was applied and
Child–Pugh score eliminated ﬁrst in both the EASL and mRECIST
models as it did not improve the model ﬁt. We have also added
Child–Pugh score back into our ﬁnal models and, again, it did
not improve the ﬁt.
Wang et al. also question whether a single assessment of
response is appropriate. For studies in which response is the
primary end point, we agree that conﬁrmation of response is
relevant. However, our study speciﬁcally investigated whether
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